Alpfa Medical, Inc. — SEC Form D Filing

Alpfa Medical, Inc. filed an SEC Form D on September 26, 2026, reporting $80.27M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
September 26, 2026
Amount reported
$80.27M
Round stage
Seed
Industry
Medical Devices
Website
https://www.alpfamed.com/

What the company does

Securities: Equity, Offering of preferred stock and the underlying common stock issuable upon conversion of the preferred stock.. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Benign Prostatic Hyperplasia (BPH) is a condition affecting millions of men where an enlarged prostate compresses the urethra, causing difficult urination. Existing treatments for BPH can carry risks such as bleeding, pain, catheterization, and unintended effects on urinary or sexual function, causing men to hesitate in seeking treatment.

Solution

Alpfa Medical is developing ALPFA GRAIL, a medical device system that uses Pulsed Field Ablation (PFA) to deliver targeted electrical energy without heat to remodel prostate tissue and restore elasticity. This minimally invasive treatment is designed to break down prostate cells while preserving surrounding structures to restore normal urinary flow.

Why now

There is a growing demand for less invasive and safer treatment options for common conditions like BPH, especially as the population ages and patients become more informed about treatment risks and benefits. New ablation technologies like pulsed field ablation are emerging as viable alternatives to traditional surgical or thermal methods.

Verdict

Investors backed this because the PFA technology offered a differentiated approach to a known, large clinical problem with clear patient benefit, not because the company demonstrated superior commercialization strategy. They were implicitly betting on a favorable clinical development and regulatory pathway for a novel energy source in a crowded indication. Upside was limited by the potential for existing incumbents to adapt or for clinical data to reveal unexpected side effects, constraining broad adoption beyond early adopters.

Source: SEC EDGAR Form D filing